Apixaban for Extended Treatment of Venous Thromboembolism
Open accessThe DOI matches its Crossref record, with a small difference in title or year; 19 of the 19 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Apixaban, an oral factor Xa inhibitor that can be administered in a simple, fixed-dose regimen, may be an option for the extended treatment of venous thromboembolism. METHODS: In this randomized, double-blind study, we compared two doses of apixaban (2.5 mg and 5 mg, twice daily) with placebo in patients with venous thromboembolism who had completed 6 to 12 months of anticoagulation therapy and for whom there was clinical equipoise regarding the continuation or cessation of anticoagulation therapy. The study drugs were administered for 12 months. RESULTS: A total of 2486 patients underwent randomization, of whom 2482 were included in the intention-to-treat analyses. Symptomatic recurrent venous thromboembolism or death from venous thromboembolism occurred in 73 of the 829 patients (8.8%) who were receiving placebo, as compared with 14 of the 840 patients (1.7%) who were receiving 2.5 mg of apixaban (a difference of 7.2 percentage points; 95% confidence interval [CI], 5.0 to 9.3) and 14 of the 813 patients (1.7%) who were receiving 5 mg of apixaban (a difference of 7.0 percentage points; 95% CI, 4.9 to 9.1) (P<0.001 for both comparisons). The rates of major bleeding were 0.5% in the placebo group, 0.2% in the 2.5-mg apixaban group, and 0.1% in the 5-mg apixaban group. The rates of clinically relevant nonmajor bleeding were 2.3% in the placebo group, 3.0% in the 2.5-mg apixaban group, and 4.2% in the 5-mg apixaban group. The rate of death from any cause was 1.7% in the placebo group, as compared with 0.8% in the 2.5-mg apixaban group and 0.5% in the 5-mg apixaban group. CONCLUSIONS: Extended anticoagulation with apixaban at either a treatment dose (5 mg) or a thromboprophylactic dose (2.5 mg) reduced the risk of recurrent venous thromboembolism without increasing the rate of major bleeding. (Funded by Bristol-Myers Squibb and Pfizer; AMPLIFY-EXT ClinicalTrials.gov number, NCT00633893.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“For the baseline risk of major bleeding, we used data from 2 randomized trials on people with VTE, showing that the risk of major bleeding with placebo during 18 or 24 months of follow-up was as low as 0.5% 306 and as high as 1.5% in 18 months. 259”
From American Society of Hematology 2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolism (2020) · cites this paper as [306]
In the citing paper
“We identified 2 RCTs 306,314 to inform this recommendation.”
From American Society of Hematology 2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolism (2020) · cites this paper as [306]
In the citing paper
“Two of these agents, rivaroxaban and apixaban, have been studied at a reduced dose: from 20 mg daily to 10 mg daily for rivaroxaban and 5 mg to 2.5 mg twice daily for apixaban. 306,314”
From American Society of Hematology 2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolism (2020) · cites this paper as [306]
In the citing paper
“Three DOACs have been studied for secondary prevention of recurrent VTE after completion of the primary treatment phase. 306,310,314”
From American Society of Hematology 2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolism (2020) · cites this paper as [306]
Citations
Cites
Apixaban versus warfarin in patients with atrial fibrillation
Granger, C. B., Alexander, J. H., McMurray, J. J. V., Lopes, R. D., Hylek, E. M., Hanna, M., Al-Khalidi, H. R., Ansell, J., Atar, D., Avezum, A., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1107039 · Cited by 8,943
Kearon (2012) · doi:10.1378/chest.11-2301 · Cited by 6,119
A sharper Bonferroni procedure for multiple tests of significance
HOCHBERG, Y. (1988) · Biometrika · doi:10.1093/biomet/75.4.800 · Cited by 4,829
Oral Rivaroxaban for Symptomatic Venous Thromboembolism
(2010) · New England Journal of Medicine · doi:10.1056/nejmoa1007903 · Cited by 3,237
Guidelines on the diagnosis and management of acute pulmonary embolism
Authors/Task Force Members, Torbicki, A., Perrier, A., Konstantinides, S., Agnelli, G., Galiè, N., Pruszczyk, P., Bengel, F., Brady, A. J. B., Ferreira, D., et al. (2008) · European Heart Journal · doi:10.1093/eurheartj/ehn310 · Cited by 2,826
Self-citationApixaban in patients with atrial fibrillation
Connolly, S. J., Eikelboom, J., Joyner, C., Diener, H.-C., Hart, R., Golitsyn, S., Flaker, G., Avezum, A., Hohnloser, S. H., Diaz, R., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1007432 · Cited by 2,483
Pulmonary embolism and deep vein thrombosis
Goldhaber, S. Z., & Bounameaux, H. (2012) · The Lancet · doi:10.1016/s0140-6736(11)61904-1 · Cited by 1,054
Long-Term, Low-Intensity Warfarin Therapy for the Prevention of Recurrent Venous Thromboembolism
Ridker, P. M., Goldhaber, S. Z., Danielson, E., Rosenberg, Y., Eby, C. S., Deitcher, S. R., Cushman, M., Moll, S., Kessler, C. M., Elliott, C. G., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa035029 · Cited by 808
Kearon, C., Ginsberg, J. S., Kovacs, M. J., Anderson, D. R., Wells, P., Julian, J. A., MacKinnon, B., Weitz, J. I., Crowther, M. A., Dolan, S., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa035422 · Cited by 751
Self-citationAspirin for Preventing the Recurrence of Venous Thromboembolism
Becattini, C., Agnelli, G., Schenone, A., Eichinger, S., Bucherini, E., Silingardi, M., Bianchi, M., Moia, M., Ageno, W., Vandelli, M. R., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1114238 · Cited by 620
Self-citation
Research works printed but not linked: 1
- Schulman S, 2011, J Thromb Haemost, 9, 22
Cited by
Items 401–500 of 1,000
Phillippe, H. M., Hornsby, L. B., Eudaley, S. T., Armstrong, E. M., & Bellone, J. M. (2014) · Journal of Pharmacy Practice · doi:10.1177/0897190014530390 · Cited by 29
Use of novel oral anticoagulant agents in venous thromboembolism
Madan, S., Shah, S., Dale, P., Partovi, S., & Parikh, S. A. (2016) · Cardiovascular Diagnosis and Therapy · doi:10.21037/cdt.2016.11.17 · Cited by 23
“AMPLIFY-EXT was a follow-up study to evaluate use of apixaban as an option for extended treatment of VTE (32).”
BackgroundBromley, A., & Plitt, A. (2018) · Cardiology and Therapy · doi:10.1007/s40119-018-0107-0 · Cited by 21
“The results of AMPLIFY-EXT are limited by the patient characteristics of the study, principally the fact that only 15% of the patients studied were greater than 75 years of age and over 90% of patients had a creatinine clearance (CrCL) greater than 50 ml/min.”
BackgroundInfluentialCohen, A. T., Berger, S. E., Milenković, D., Hill, N. R., & Lister, S. (2019) · Pharmacological Research · doi:10.1016/j.phrs.2019.03.017 · Cited by 22
Self-citationSalakolusu, S., Sharma, G. V. R., Katari, N. K., Puppala, U., Kaliyapermal, M., Vijay, R., Doddipalla, R., & Geereddi, M. K. R. (2022) · Journal of Separation Science · doi:10.1002/jssc.202200466 · Cited by 21
Treating cancer-associated venous thromboembolism: A practical approach
Cutsem, E. V., Mahé, I., Felip, E., Agnelli, G., Awada, A. H., Cohen, A. T., Falanga, A., Mandalà, M., Peeters, M., Tsoukalas, N., et al. (2024) · European Journal of Cancer · doi:10.1016/j.ejca.2024.114263 · Cited by 21
Self-citationOptimal treatment duration of venous thrombosis
Ageno, W., Dentali, F., Donadini, M. P., & Squizzato, A. (2013) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.12234 · Cited by 21
Novel Anticoagulant Therapy of Venous Thromboembolism: Current Status and Future Directions
Nakamura, M., Yamada, N., & Ito, M. (2017) · Annals of Vascular Diseases · doi:10.3400/avd.ra.17-00015 · Cited by 24
Tomkowski, W. Z., Kuca, P., Urbanek, T., Chmielewski, D., Krasiński, Z., Pruszczyk, P., Windyga, J., Oszkinis, G., Jawień, A., Burakowski, J., et al. (2017) · Acta Angiologica · doi:10.5603/aa.2017.0008 · Cited by 27
Tarango, C., Schulman, S., Betensky, M., & Goldenberg, N. A. (2017) · Expert Review of Hematology · doi:10.1080/17474086.2018.1407241 · Cited by 21
“In the last decade, VTE treatment trials with the non-vitamin K direct oral anticoagulants (DOACs), which include oral direct thrombin inhibitors and Xa inhibitors, have demonstrated efficacy of these agents in secondary VTE prevention, with similar or better safety profiles than warfarin [32–35] DOACs have also been…”
BackgroundYamashita, Y., Yoshikawa, Y., Morimoto, T., Amano, H., Takase, T., Hiramori, S., Kim, K., Oi, M., Akao, M., Kobayashi, Y., et al. (2019) · International Journal of Cardiology · doi:10.1016/j.ijcard.2019.06.032 · Cited by 25
Danaparoid sodium-based anticoagulation therapy for portal vein thrombosis in cirrhosis patients
Hayashi, T., Takatori, H., Horii, R., Nio, K., Terashima, T., Iida, N., Kitahara, M., Shimakami, T., Arai, K., Kitamura, K., et al. (2019) · BMC Gastroenterology · doi:10.1186/s12876-019-1140-8 · Cited by 21
Biagioni, R. B., Lópes, R. D., Agati, L. B., Sacilotto, R., Wolosker, N., Sobreira, M. L., Freitas, B., Joviliano, E. É., Bernardi, W. H., Júnior, V. C., et al. (2020) · American Heart Journal · doi:10.1016/j.ahj.2020.06.010 · Cited by 22
Oral anticoagulants in the management of venous thromboembolism
Makaryus, J. N., Halperin, J. L., & Lau, J. F. (2013) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2013.73 · Cited by 28
Rudd, K. M., & Phillips, E. (. M. (2013) · Thrombosis · doi:10.1155/2013/973710 · Cited by 20
“The majority of patients on apixaban in AMPLIFY-EXT weighed greater than 60 kg (92.6%).”
BackgroundInfluentialA comprehensive evaluation of apixaban in the treatment of venous thromboembolism
Koehl, J. L., Hayes, B. D., Al-Samkari, H. T., & Rosovsky, R. P. G. (2020) · Expert Review of Hematology · doi:10.1080/17474086.2020.1711731 · Cited by 21
“Two multinational, randomized, double-blind, phase III trials in adult patients examined the efficacy of apixaban for the initial treatment of acute VTE (symptomatic, proximal DVT and/or PE) over 6 months in the Apixaban for the Initial Management of Pulmonary Embolism and Deep-Vein Thrombosis as First-Line Therapy (A…”
MethodCurrent Perspectives of Anticoagulation in Patients With COVID-19
Gavioli, E. M., Sikorska, G., Man, A., Rana, J., & Vider, E. (2020) · Journal of Cardiovascular Pharmacology · doi:10.1097/fjc.0000000000000861 · Cited by 20
Extended Anticoagulation After Pulmonary Embolism: A Multicenter Observational Cohort Analysis
Chopard, R., Albertsen, I. E., Ecarnot, F., Guth, S., Besutti, M., Falvo, N., Piazza, G., & Meneveau, N. F. (2022) · Journal of the American Heart Association · doi:10.1161/jaha.121.024425 · Cited by 22
Bauersachs, R. M. (2014) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2014.05.017 · Cited by 20
“Efficacy and safety outcomes were consistent with the observed overall treatment effects, although it was noted thatmore data are needed to better determine the benefit–risk profile of apixaban with respect to bleeding in frail patients [53].”
BackgroundResultInfluentialDirect oral anticoagulants: unique properties and practical approaches to management
Barnes, G. D., & Kurtz, B. (2016) · Heart · doi:10.1136/heartjnl-2015-309075 · Cited by 22
Calderone, A., Stevens, W., Prior, D., Nandurkar, H. H., Gabbay, E., Proudman, S., Williams, T. J., Celermajer, D. S., Sahhar, J., Wong, P. K. K., et al. (2016) · BMJ Open · doi:10.1136/bmjopen-2016-011028 · Cited by 21
Jiang, Q., Bai, J., Jin, J., Shi, J., & Qu, L. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.00876 · Cited by 20
“Clinical trials have shown that the efficacies of new oral anticoagulants (NOACs) and aspirin are non-inferior to warfarin (Becattini et al., 2012; Agnelli et al., 2013; Schulman et al., 2013).”
BackgroundPatel, A., Williams, H., Baer, M. R., Zimrin, A. B., & Law, J. Y. (2019) · Acta Haematologica · doi:10.1159/000500223 · Cited by 20
Special Considerations in Pulmonary Embolism
Kabrhel, C., Rosovsky, R. P. G., & Garvey, S. R. (2020) · Critical Care Clinics · doi:10.1016/j.ccc.2020.02.008 · Cited by 20
Pompilio, G., Integlia, D., Raffetto, J. D., & Palareti, G. (2020) · TH Open · doi:10.1055/s-0040-1709731 · Cited by 21
Clinical Experience With the New Oral Anticoagulants for Treatment of Venous Thromboembolism
Bacchus, F., & Schulman, S. (2014) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.114.303396 · Cited by 23
“pleted 6 to 12 months of anticoagulation for VTE in the AMPLIFY-EXT study.(25) The study design uniquely randomized patients to different doses of apixaban, 5 mg twice daily or 2.”
BackgroundMethodWang, Q., Sun, Q., Tang, P., Tang, B., He, J., Ma, X., & Li, H. (2015) · RSC Advances · doi:10.1039/c5ra15430h · Cited by 21
Prandoni, P. (2014) · Thrombosis Research · doi:10.1016/j.thromres.2014.05.013 · Cited by 21
“A net clinical benefit was also observedwith both doses of apixaban (defined as a reduction in the composite of symptomatic, recurrent VTE, death related to VTE, myocardial infarction, stroke, death related to cardiovascular disease or major bleeding) [28].”
BackgroundMethodResultMerali, S. J., Byon, W., Myers, E., Li, X., Marchisin, D., & Murthy, B. (2019) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-019-00348-2 · Cited by 20
“Apixaban is an oral, selective, direct-reversible inhibitor of coagulation factor Xa that is approved in a number of countries for thromboprophylaxis in patients who have undergone elective hip or knee replacement surgery [1–3], for reducing the risk of stroke and systemic embolism in patients with nonvalvular atrial…”
BackgroundInfluentialCada, D. J., Levien, T. L., & Baker, D. E. (2013) · Hospital Pharmacy · doi:10.1310/hpj4806-494 · Cited by 22
Rollins, B. M., Silva, M. A., Donovan, J. L., & Kanaan, A. O. (2014) · Clinical Therapeutics · doi:10.1016/j.clinthera.2014.06.033 · Cited by 18
Coleman, C. I., Limone, B. L., Bookhart, B. K., Mody, S. H., & Nutescu, E. A. (2014) · Thrombosis Research · doi:10.1016/j.thromres.2014.02.006 · Cited by 18
“While each of these agents have been compared to placebo for extended VTE treatment [1,6,7,13,4,18,40–43], only dabigatran [42] has been compared to warfarin as part of a head-to-head randomized trial.”
BackgroundMethodInfluentialDiretrizes sobre trombose venosa profunda da Sociedade Brasileira de Angiologia e Cirurgia Vascular
Sobreira, M. L., Marques, M. A., Paschôa, A. F., Ribeiro, A. J. A., Casella, I. B., Burihan, M. C., Matielo, M. F., Soares, R. D. A., de Araújo, W. J. B., Joviliano, E. É., et al. (2024) · Jornal Vascular Brasileiro · doi:10.1590/1677-5449.202301071 · Cited by 27
“Para o tratamento na fase aguda do TEV, recomenda-se a dose de 10 mg, via oral, duas vezes ao dia por 5 dias, depois, 5 mg, duas vezes ao dia 91,94,95 .”
BackgroundWeitz, J. I., & Chan, N. (2019) · Thrombosis and Haemostasis · doi:10.1055/s-0039-1679906 · Cited by 18
Self-citationEbraheem, M. S., Alzahrani, I., Crowther, M. A., Rochwerg, B. N., & Almakadi, M. (2020) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.14949 · Cited by 22
Apixaban Pharmacokinetics and Pharmacodynamics in Subjects with Mild or Moderate Hepatic Impairment
Frost, C. E., Ly, V. T., & Merali, S. J. (2021) · Drugs in R&D · doi:10.1007/s40268-021-00359-y · Cited by 20
Lüscher, T. F., Davies, A. J., Beer, J. H., Valgimigli, M., Nienaber, C. A., Camm, A. J., Baumgärtner, I., Diener, H., & Konstantinides, S. (2021) · European Heart Journal · doi:10.1093/eurheartj/ehab642 · Cited by 21
Apixaban Prophylactic Anticoagulation in Patients with Nephrotic Syndrome
Meerhaeghe, T. V., Cez, A., Dahan, K., Estève, E., Elalamy, I., Boffa, J. J., & Ponlot, E. (2022) · TH Open · doi:10.1055/a-1920-6224 · Cited by 20
Choice and Duration of Anticoagulation for Venous Thromboembolism
Barnes, G. D., Malik, A., & Ha, N. B. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13010301 · Cited by 26
“In AMPLIFY-EXTEND, apixaban 5 mg BID was compared to apixaban 2.5 mg BID and placebo, demonstrating similar rates of recurrent VTE in both apixaban groups and superiority to the placebo group [14].”
MethodInfluentialKovac, M. K., Ignjatović, V., Orlando, C., Bereczky, Z., & Hunt, B. J. (2024) · Journal of Thrombosis and Haemostasis · doi:10.1016/j.jtha.2024.08.006 · Cited by 21
Thrombophilia Testing, Recurrent Thrombosis, and Women’s Health
Piazza, G. (2014) · Circulation · doi:10.1161/circulationaha.113.007664 · Cited by 19
Uresandi, F., Monréal, M., García-Bragado, F., Domenech, P., Lecumberri, R., Escribano, P., Zamorano, J. L., Jiménez, S., Ruiz‐Artacho, P., Lozano, F., et al. (2013) · Archivos de Bronconeumología · doi:10.1016/j.arbr.2013.10.008 · Cited by 40
Hernandez, C. M. R., Oo, T. H., & García‐Perdomo, H. A. (2016) · Journal of Thrombosis and Thrombolysis · doi:10.1007/s11239-016-1434-4 · Cited by 18
Woller, S. C., Stevens, S. M., Johnson, S. A., Bledsoe, J. R., Galovic, B., Lloyd, J. F., Wilson, E. L., Armbruster, B. P., & Evans, R. S. (2019) · Research and Practice in Thrombosis and Haemostasis · doi:10.1002/rth2.12208 · Cited by 21
Medeiros, S. K., Emery, B., Bhagirath, V. C., Parpia, S., Dwivedi, D. J., Dwivedi, N. J., Kearon, C., & Liaw, P. C. (2019) · Thrombosis Research · doi:10.1016/j.thromres.2019.11.030 · Cited by 20
Li, M., Li, J., Wang, X., Xu, H., Wang, Q., Xie, S., Yan, P., Tian, J., Li, J., Xie, P., et al. (2023) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd010957.pub3 · Cited by 26
Myers, J. A., Wittenburg, L. A., Olver, C. S., Martinez, C. M., & Bright, J. M. (2015) · American Journal of Veterinary Research · doi:10.2460/ajvr.76.8.732 · Cited by 18
Direct oral anticoagulants: integration into clinical practice
Cowell, R. P. W. (2014) · Postgraduate Medical Journal · doi:10.1136/postgradmedj-2013-132474 · Cited by 23
Statin Therapy to Revert Hypercoagulability and Prevent Venous Thromboembolism: A Narrative Review
Orsi, F. A., Cannegieter, S. C., & Lijfering, W. M. (2019) · Seminars in Thrombosis and Hemostasis · doi:10.1055/s-0039-1687911 · Cited by 21
Extended Treatment of Venous Thromboembolism
Connors, J. M. (2013) · New England Journal of Medicine · doi:10.1056/nejme1215678 · Cited by 19
Expanding use of new oral anticoagulants
Weitz, J. I. (2014) · F1000Prime Reports · doi:10.12703/p6-93 · Cited by 18
Self-citationDirect oral anticoagulants in the treatment and long-term prevention of venous thrombo-embolism
Fontana, P., Goldhaber, S. Z., & Bounameaux, H. (2014) · European Heart Journal · doi:10.1093/eurheartj/ehu027 · Cited by 22
Cancer‐associated venous thromboembolism: Incidence and features in a racially diverse population
Raskob, G. E., Wendelboe, A. M., Campbell, J. E., Ford, L., Ding, K., Bratzler, D. W., McCumber, M. D., Adamski, A., Abe, K., Beckman, M. G., et al. (2022) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.15818 · Cited by 20
Self-citationKobayashi, R., Cetatoiu, M. A., Esteso, P., Ventresco, C., Hawkins, B., Daly, K. P., Blume, E. D., Fynn‐Thompson, F., & VanderPluym, C. J. (2023) · ASAIO Journal · doi:10.1097/mat.0000000000001889 · Cited by 21
Talerico, R., Pola, R., Klok, F. A., & Huisman, M. V. (2024) · TH Open · doi:10.1055/s-0043-1776989 · Cited by 20
May, J. E., & Moll, S. (2024) · Blood · doi:10.1182/blood.2023021638 · Cited by 21
Bleeding complications of targeted oral anticoagulants: what is the risk?
Levine, M., & Goldstein, J. N. (2014) · Hematology · doi:10.1182/asheducation-2014.1.504 · Cited by 20
Cohen, A. T., Buller, H. R., Agnelli, G., Gallus, A. S., Raskob, G. E., Weitz, J. I., Curto, M., Sisson, M., Middeldorp, S., & Bleker, S. M. (2016) · Thrombosis and Haemostasis · doi:10.1160/th16-02-0137 · Cited by 17
“Extended treatment of VTE with apixaban reduced the risk of recurrent VTE without increasing the rate of major bleeding (3).”
BackgroundSelf-citationChopard, R., Serzian, G., Humbert, S., Falvo, N., Morel-Aleton, M., Bonnet, B., Napporn, G., Kalbacher, E., Obert, L., Degano, B., et al. (2018) · Journal of Thrombosis and Thrombolysis · doi:10.1007/s11239-018-1690-6 · Cited by 18
Who should get long-term anticoagulant therapy for venous thromboembolism and with what?
Rodger, M. A., & Gal, G. L. (2018) · Hematology · doi:10.1182/asheducation-2018.1.426 · Cited by 17
Sebastian, T., Engelberger, R. P., Spirk, D., Hakki, L. O., Baumann, F. A., Spescha, R. S., & Kucher, N. (2019) · VASA · doi:10.1024/0301-1526/a000774 · Cited by 17
Hendriks, T., McGregor, S., Rakesh, S., Robinson, J., Ho, K. M., & Baker, R. I. (2020) · PLoS ONE · doi:10.1371/journal.pone.0234048 · Cited by 17
“[8, 9] Patient satisfaction with medication is an important determinant of long-term patient compliance.”
BackgroundRivaroxaban for the Treatment of Pulmonary Embolism
Vanassche, T., & Verhamme, P. B. (2013) · Advances in Therapy · doi:10.1007/s12325-013-0041-4 · Cited by 18
“assured effective prevention of recurrent VTE with a reduced incidence of bleeding complications [12] (Fig.”
BackgroundMethodBova, C., Bianco, A., Mascaro, V., & Nobile, C. G. A. (2016) · Thrombosis Research · doi:10.1016/j.thromres.2016.01.005 · Cited by 18
Trends in Pulmonary Embolism Outcomes
Konstantinides, S. (2016) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2015.10.062 · Cited by 17
Frost, C. E., Merali, S. J., Shenker, A., Barrett, Y. C., & LaCreta, F. P. (2021) · Clinical Pharmacology in Drug Development · doi:10.1002/cpdd.990 · Cited by 19
Su, X., Yan, B., Wang, L., Cheng, H., & Chen, Y. (2022) · BMJ Open · doi:10.1136/bmjopen-2021-048619 · Cited by 17
“The details of the efficacy outcomes are presented in figure 2.”
Khan, F. A., Coyle, D., Thavorn, K., van Katwyk, S., Tritschler, T., Hutton, B., Gal, G. L., Rodger, M. A., & Fergusson, D. A. (2023) · Annals of Internal Medicine · doi:10.7326/m22-3559 · Cited by 17
“59% (12, 13), our results showed a 99% probability of an incremental benefit in QALYs (albeit a 0% chance of being cost-effective).”
BackgroundKonstantinides, S., Torbicki, A., Agnelli, G., Danchin, N., Fitzmaurice, D. A., Galiè, N., Gibbs, J. S. R., Huisman, M. V., Humbert, M. J. C., Kucher, N., et al. (2014) · Revista Española de Cardiología · doi:10.1016/j.recesp.2014.12.002 · Cited by 25
Self-citationLanitis, T., Leipold, R. J., Hamilton, M., Rublee, D. A., Quon, P., Browne, C., & Cohen, A. T. (2017) · BMC Health Services Research · doi:10.1186/s12913-017-1995-8 · Cited by 16
“AMPLIFY-EXT enrolled a population of patients previously treated for 6–12 months for whom there was clinical equipoise about the continuation of anticoagulation therapy [13].”
BackgroundMethodInfluentialSelf-citationPulmonary embolism: Care standards in 2018
Borohovitz, A., Weinberg, M. D., & Weinberg, I. (2017) · Progress in Cardiovascular Diseases · doi:10.1016/j.pcad.2017.12.005 · Cited by 16
“Three studies addressed reduced dose TT in VTE.”
InfluentialPredicting the risk of recurrent venous thrombosis: What the future might bring
Lijfering, W. M., Timp, J. F., & Cannegieter, S. C. (2019) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.14534 · Cited by 21
Papakonstantinou, P. Ε., Tsioufis, C. P., Konstantinidis, D., Iliakis, P., Leontsinis, I., & Tousoulis, D. M. (2020) · Current Pharmaceutical Design · doi:10.2174/1381612826666200420150517 · Cited by 17
Recent advances in understanding, diagnosing and treating venous thrombosis
Chan, N., & Weitz, J. I. (2020) · F1000Research · doi:10.12688/f1000research.27115.1 · Cited by 18
Self-citationAsady, E., Ghanima, W., Jelsness‐Jørgensen, L., Klok, F. A., Kahn, S. R., Strømme, H., & Wik, H. S. (2021) · Research and Practice in Thrombosis and Haemostasis · doi:10.1002/rth2.12556 · Cited by 19
Direct oral anticoagulants: a guide for daily practice
Fontana, P., Robert‐Ebadi, H., Bounameaux, H., Boehlen, F., & Righini, M. (2016) · Swiss Medical Weekly · doi:10.4414/smw.2016.14286 · Cited by 22
Management of pulmonary embolism: recent evidence and the new European guidelines
Konstantinides, S., & Torbicki, A. (2014) · European Respiratory Journal · doi:10.1183/09031936.00180414 · Cited by 19
Anticoagulation therapy in 2015: where we are and where we are going
Weitz, J. I. (2015) · Journal of Thrombosis and Thrombolysis · doi:10.1007/s11239-015-1194-6 · Cited by 15
Self-citationBikdeli, B., Hogan, H., Morrison, R. B., Fanikos, J. R., Campia, U., Barns, B. M., Pfeferman, M. B., Snyder, J. E., Khairani, C. D., Goldhaber, S. Z., et al. (2021) · Thrombosis and Haemostasis · doi:10.1055/a-1646-2244 · Cited by 16
Challenging clinical scenarios for therapeutic anticoagulation: A practical approach
Martens, K. L., Dekker, S. E., Crowe, M. E., DeLoughery, T. G., & Shatzel, J. J. (2022) · Thrombosis Research · doi:10.1016/j.thromres.2022.08.015 · Cited by 18
Zalpour, A., & Oo, T. H. (2015) · Advances in Hematology · doi:10.1155/2015/920361 · Cited by 15
“Although data is available for extended treatment for VTE with apixaban or rivaroxaban [68, 69], limited data exists for edoxaban.”
BackgroundWeir, M. R., & Kreutz, R. H. (2018) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2018.06.018 · Cited by 16
Nazha, B., Pandya, B., Spyropoulos, A. C., & Kessler, C. M. (2018) · Seminars in Thrombosis and Hemostasis · doi:10.1055/s-0038-1673690 · Cited by 16
Review of Direct Oral Anticoagulants and Guide for Effective Drug Utilization
Khachatryan, T., Hauschild, C., Hoff, J., Contractor, T. A., Khachatryan, A., Tran, H. N., Matsuo, B., Jacobson, A. K., & Hilliard, A. A. (2019) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-019-00344-6 · Cited by 15
ESC-Leitlinien 2019 zu Diagnostik und Management der akuten Lungenembolie
Osteresch, R., Fach, A., Hambrecht, R., & Wienbergen, H. (2019) · Herz · doi:10.1007/s00059-019-04863-5 · Cited by 17
Bleeding risk in patients with venous thromboembolic events treated with new oral anticoagulants
Wallvik, N., Renlund, H., & Själander, A. (2020) · Journal of Thrombosis and Thrombolysis · doi:10.1007/s11239-020-02319-w · Cited by 16
“Extended anticoagulation with low dose NOAC in clinical equipoise situations is supported by two RCTs [23, 24].”
MethodInfluentialMavromanoli, A. C., Barco, S., & Konstantinides, S. (2021) · Research and Practice in Thrombosis and Haemostasis · doi:10.1002/rth2.12509 · Cited by 16
Liu, X., Thompson, J. R., Phatak, H. M., Mardekian, J., Porcari, A. R., Johnson, M. R., & Cohen, A. T. (2015) · Thrombosis and Haemostasis · doi:10.1160/th15-07-0606 · Cited by 17
“Key inclusion criteria included age ≥ 18 years; objectively confirmed symptomatic deep vein thrombosis (DVT) or pulmonary embolism (PE; with or without DVT); 6–12 months of previous treatment with standard anticoagulant therapy or completion of treatment with apixaban or enoxaparin and warfarin during AMPLIFY; no symp…”
BackgroundMethodSelf-citationAhmed, Z., Hassan, S., & Salzman, G. A. (2016) · Current Drug Therapy · doi:10.2174/1574885511666160421145036 · Cited by 15
“The limitations of the trial include short term follow up of one year only and few patients with cancer, age above 75 years, low body weight below 60 kg or severe renal dysfunction [21].”
ANMCO Position Paper: long-term follow-up of patients with pulmonary thromboembolism
D’Agostino, C., Zonzin, P., Enea, I., Gulizia, M. M., Ageno, W., Agostoni, P., Azzarito, M., Becattini, C., Bongarzoni, A., Bux, F., et al. (2017) · European Heart Journal Supplements · doi:10.1093/eurheartj/sux030 · Cited by 16
Wakakura, S., Hara, F., Fujino, T., Hamai, A., Ohara, H., Kabuki, T., Harada, M., & Ikeda, T. (2017) · International Heart Journal · doi:10.1536/ihj.16-482 · Cited by 16
the COMMAND VTE Registry Investigators, Yamashita, Y., Morimoto, T., Amano, H., Takase, T., Hiramori, S., Kim, K., Oi, M., Akao, M., Kobayashi, Y., et al. (2019) · Journal of Thrombosis and Thrombolysis · doi:10.1007/s11239-018-1791-2 · Cited by 16
Venous thromboembolism: current management
Stevens, H., Tran, H. A., & Gibbs, H. H. (2019) · Australian Prescriber · doi:10.18773/austprescr.2019.039 · Cited by 18
Thrombotic complications with interruption of direct oral anticoagulants in dermatologic surgery
Siscos, S. M., Neill, B. C., Singh, A. H., & Hocker, T. L. H. (2020) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2020.10.008 · Cited by 15
Ткачева, О. Н., Vorobyeva, N. M., Kotovskaya, Y. V., Рунихина, Н. К., Strazhesko, I. D., Вадимовна, В. С., Drapkina, O. M., Komarov, A. L., Orlova, Y. A., Панченко, Е. П., et al. (2021) · CARDIOVASCULAR THERAPY AND PREVENTION · doi:10.15829/1728-8800-2021-2847 · Cited by 15
Adamantidi, T., Pisioti, M. S., Pitsouni, S., Maria, C., Georgios, K., Dania, V., Vordos, N., Krokidis, X., & Τσούπρας, Α. (2025) · Current Issues in Molecular Biology · doi:10.3390/cimb47040291 · Cited by 15
“However, the decision to continue or discontinue anticoagulation therapy must weigh the benefits of lowering VTE recurrence against the increased risk of bleeding [131,211–214].”
Efficacy and Toxicity of Factor Xa Inhibitors
Bondarenko, M., Curti, C., Montana, M., Rathelot, P., & Vanelle, P. (2013) · Journal of Pharmacy & Pharmaceutical Sciences · doi:10.18433/j33p49 · Cited by 14
Importance of subsegmental pulmonary embolism
Raskob, G. E. (2013) · Blood · doi:10.1182/blood-2013-06-508440 · Cited by 15
Self-citationCurrent State of Anticoagulants to Treat Deep Venous Thrombosis
Vo, T. L., Vazquez, S. R., & Rondina, M. T. (2014) · Current Cardiology Reports · doi:10.1007/s11886-013-0463-2 · Cited by 14
Pharmacotherapy with oral Xa inhibitors for venous thromboembolism
Vanassche, T., Vandenbriele, C., Peerlinck, K., & Verhamme, P. B. (2015) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2015.999043 · Cited by 16
“2 Similarities in trials The Phase III programs of rivaroxaban [8,9], apixaban [10,11] and edoxaban [12] are summarized in Table 3.”
Background
Metadata
- Authors
- Agnelli, G., Buller, H. R., Cohen, A., Curto, M., Gallus, A. S., Johnson, M., Porcari, A., Raskob, G. E., & Weitz, J. I.
- Affiliations
- University of Perugia (IT)
- Amsterdam UMC Location University of Amsterdam (NL)
- King's College Hospital (GB)
- McMaster University (CA)
- Flinders University (AU)
- University of Oklahoma Health Sciences Center (US)
- Thrombosis and Atherosclerosis Research Institute (CA)
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2013-02-21
- Volume
- 368
- Issue
- 8
- Pages
- 699-708
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2139785591
- Cited by
- 1,366
- References
- 19
- Citations by year
- 2026: 70 · 2025: 80 · 2024: 64 · 2023: 68 · 2022: 90 · 2021: 98 · 2020: 101 · 2019: 114 · 2018: 103 · 2017: 89 · 2016: 109 · 2015: 133 · 2014: 141 · 2013: 102
- FWCI
- 81.60
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Dipòsit Digital de la Universitat de Barcelona (Universitat de Barcelona) (submittedVersion, public-domain)
- Data Archiving and Networked Services (DANS) (submittedVersion)
- HAL (submittedVersion)
- Pure Amsterdam UMC (submittedVersion)
- Padua Research Archive (University of Padova) (submittedVersion)
- Funders
- Bristol-Myers Squibb
- Pfizer
- GlaxoSmithKline
- Sanofi
- Bayer HealthCare
- Daiichi Sankyo Europe
- Topics
- Health Sciences › Medicine › Internal Medicine › Venous Thromboembolism Diagnosis and Management
- Health Sciences › Medicine › Hematology › Blood Coagulation and Thrombosis Mechanisms
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Atrial Fibrillation Management and Outcomes
- Keywords
- apixaban, venous thromboembolism, long-term anticoagulation, factor Xa inhibitors, recurrent venous thromboembolism, thromboprophylaxis, major bleeding, mortality, dose comparison, oral anticoagulants, clinical equipoise, post-thrombotic syndrome, pulmonary embolism, deep vein thrombosis
- MeSH terms
- Adult, Aged, Creatinine, Double-Blind Method, Female, Fibrinolytic Agents, Follow-Up Studies, Hemorrhage, Humans, Male, Middle Aged, Pyrazoles, Pyridones, Recurrence, Treatment Outcome, Kaplan-Meier Estimate, Venous Thromboembolism, Intention to Treat Analysis, Factor Xa Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.